Afrigen Biologics (Pty) Ltd

Made in Africa mRNA Vaccines: A talk with Dr. Petro Terblanche of Afrigen Biologics & Vaccine. ⏭️Ben recently sat down with Dr. Petro Terblanche, the head of Afrigen, Africa’s first #mRNA vaccine researcher and manufacturer. From the calamities of COVID-19 vaccine populism, the African public health community & its allies swore that never again would Africa be last in the line when it came to life saving pandemic #vaccines, and Petro sets out how this can - and is - being achieved, notwithstanding a wide array of challenges - and opposition. Visit this link to view ⏭️ https://lnkd.in/dK85RmRt Read more ⏭️ https://kite.link/mMD8mMD #afrigenbiologics #mRNAvaccineresearcher #mRNAmanufacturer Afrigen Biologics (Pty) Ltd World Health Organization CEPI (Coalition for Epidemic Preparedness Innovations) Medicines Patent Pool Gavi, the Vaccine Alliance

Preclinical evaluation in hamster model of the #mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.    ▶️ Read more: https://lnkd.in/d44XdQBT    #mRNA  #mRNAtechnologytransferprogramme  #Afrigen  #WHO  #MPP   

Afrigen’s congratulates Bio-Sourcing on its fund-raising success and is excited to be a partner in bringing this innovative technology to Africa.    Click on this link to read more: ⏬  https://lnkd.in/d92Gsb7W    #innovativetechnology  #success  #biosourcing

"We can change the world and make it a better place. It is in your hands to make a difference"    ~ Nelson Mandela     HAPPY HERITAGE DAY     #Afrigen #Afrigenbiologics #heritageday2024

🔹Evaxion Biotech A/S obtains pre-clinical Proof-of-Concept for #mRNA Gonorrhea vaccine candidate EVX-B2🔹    🔬New pre-clinical data demonstrates that the novel EVX-B2 mRNA #vaccine candidate triggers a targeted immune response  🔬The specific immune response leads to the elimination of the gonorrhea bacteria  🔬The data confirm that Evaxion’s AI-Immunology™ platform is delivery modality agnostic    ⏬ ⏬  This new data, which will be presented today at the 18th Vaccine Congress taking place in Lisbon, Portugal, provides strong Proof-of-Concept (PoC) for the mRNA-based version of EVX-B2 in a pre-clinical setting.  EVX-B2 was initially designed as a protein-based prophylactic vaccine candidate for which pre-clinical PoC has already been obtained. The novel pre-clinical data for the mRNA-version of the vaccine substantiates that AI-Immunology™ identified vaccine antigens are delivery modality agnostic and can be applied across different vaccine modalities. The new data has been generated in collaboration with Afrigen Biologics (Pty) Ltd.    Read more: https://lnkd.in/d_XbPBAz

Udder Health Market Analysis: Current Dynamics and Emerging Trends.    Click on this link to read more ⏬    🌐 https://lnkd.in/dJKk59gu    #afrigenbiologics  #mNRA

Visit our website, www.afrigen.co.za for all the latest updates.    #afrigen  #afrigenbiologics 

CEPI partners with Afrigen to speed up #mRNAvaccine development and access. 🧬    In a US$2.05 million CEPI-funded project, #researchers at Afrigen Biologics, a South African biotech company that is home to the #mRNA Technology Transfer Programme, will explore whether optimised synthetic DNA can help to reduce mRNA vaccine development timelines for emergency use in the event of a disease outbreak. The CEPI-Afrigen partnership supports the 100 Days Mission—a goal embraced by leaders of the G7 and G20 to reduce #vaccinedevelopment timelines to a little over three months in response to a pandemic threat.    Visit the link for the full press release ⏬  https://lnkd.in/ddvF_eKY    CEPI (Coalition for Epidemic Preparedness Innovations)  @Afrigenbiologics Syngoi Technologies

AVMI recently had the honor of organizing a successful visit for the Ghanaian Minister of Health and his delegation to Afrigen Biologics, one of our esteemed manufacturing members. The visit included a comprehensive tour of Afrigen’s cutting-edge facility in Cape Town, where stakeholders engaged in meaningful information sharing. Ghanaian manufacturers and government officials were highly impressed with the innovative capabilities showcased. Afrigen Biologics (Pty) Ltd stands out as a leader in specialized vaccine production, particularly in mRNA technology. As the host of the first WHO-backed mRNA vaccine technology transfer hub in South Africa, Afrigen is at the forefront of healthcare transformation. Their modular facility structure allows for flexible adaptation to meet the evolving needs of emerging markets. Afrigen’s pioneering work includes developing vaccines for Typhoid, Gonorrhea, and HIV, addressing critical global health challenges #Ghana #SouthAfrica #Africa #Healthcare #Biotechnology #Vaccine #mRNA #AVMI #AfrigenBiologics #Manufacturing #Innovation #GlobalHealth #PublicHealth #Afrigen #WHO #VaccineTechnologyTransfer #ModularFacility #EmergingMarkets #Typhoid #Gonorrhea #HIV #AfricaCDC

🔔 #CallforProposals: Do you have an idea for a technology that can address Africa’s healthcare challenges?  Good news! We’re offering grants of up to EUR 350,000 to consortia of research institutions and private sector partners, for projects that enhance manufacturing capacity and improve access to vaccines, medicines, and health technologies in Africa. Proposals must be submitted through our application platform by the deadline of 30 September 2024. For more details, visit the GIZ South Africa Website here https://lnkd.in/d8Gs9vda or reach out to us via email at savaxjointaction@giz.de. Together with the South African National Department of Science and Innovation (DSI), this Competitive Call for Proposals is aimed at supporting innovative projects and product development. The SAVax programme (Vaccines for Africa: Roll-out and Production of Vaccines in South Africa), implemented by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH South Africa, is funded by the German Federal Ministry for Economic Cooperation and Development (BMZ) and the European Union (EU). This initiative is part of, and contributes to, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (TEI MAV+) in Africa. #GIZ #DSI #BMZ #TeamEurope #EU #Innovation #Healthcare #CallForProposals #Biotech #Pharma #Diagnostics #SAVaxJointAction